Thrombopoietin primes human platelet aggregation induced by shear stress and by multiple agonists

Atsushi Oda, Yoshitaka Miyakawa, Brian J. Druker, Katsutoshi Ozaki, Katsumi Yabusaki, Yoshiaki Shirasawa, Makoto Handa, Takashi Kato, Hiroshi Miyazaki, Akihiro Shimosaka, Yasuo Ikeda

Research output: Contribution to journalArticle

113 Citations (Scopus)

Abstract

Recombinant thrombopoietin has been reported to stimulate megakaryocytopoiesis and thrombopoiesis and it may be quite useful to treat patients with low platelet counts after chemotherapy. As little is known regarding the possible activation of platelets by thrombopoietin, we examined the effects of thrombopoietin on platelet aggregation induced by shear stress and various agonists in native plasma. Using hirudin as an anticoagulant, thrombopoietin (1 to 100 ng/mL) enhanced platelet aggregation induced by 2 μmol/L adenosine-diphosphate (ADP) in a dose dependent fashion. The enhancement was not effected by treatment of platelets with 1 mmol/L aspirin plus SQ-29548 (a thromboxane antagonist, 1 μmol/L) but was inhibited by a soluble form of the thrombopoietin receptor, suggesting that the enhancement was mediated by the specific receptors and does not require thromboxane production. Epinephrine (1 μmol/L), which does not induce platelet aggregation in hirudin platelet rich plasma (PRP), did so in the presence of thrombopoietin (10 ng/mL). Thrombopoietin (10 ng/mL) also enhanced or primed platelet aggregation induced by collagen (0.5 μg/mL), thrombin, serotonin, and vasopressin. Thrombopoietin does not induce any rise in cytosolic ionized calcium concentration nor activation of protein kinase C, as estimated by phosphorylation of preckstrin, indicating that the priming effects of thrombopoietin does not require those processes. The ADP- or thrombin- induced rise in cytosolic ionized calcium concentration was not enhanced by thrombopoietin (100 ng/mL). Further, shear (ca. 90 dyn/cm2)-induced platelet aggregation was also potentiated by thrombopoietin. The priming effect on epinephrine-induced platelet aggregation in hirudin PRP was unique to thrombopoietin, with no effects seen using interleukin-6 (IL-6), IL-11, IL- 3, erythropoietin, granulocyte-colony stimulating factor, granulocyte macrophage-colony stimulating factor, or c-kit ligand. These data indicate that monitoring of platelet functions may be necessary in the clinical trials of thrombopoietin.

Original languageEnglish
Pages (from-to)4664-4670
Number of pages7
JournalBlood
Volume87
Issue number11
Publication statusPublished - 1996 Jun 1
Externally publishedYes

Fingerprint

Thrombopoietin
Platelets
Platelet Aggregation
Shear stress
Agglomeration
Hirudins
Thrombopoiesis
Platelet-Rich Plasma
Thromboxanes
Plasmas
Thrombin
Adenosine Diphosphate
Epinephrine
Blood Platelets
Thrombopoietin Receptors
Chemical activation
Interleukin-11
Calcium
Phosphorylation
Stem Cell Factor

ASJC Scopus subject areas

  • Hematology

Cite this

Oda, A., Miyakawa, Y., Druker, B. J., Ozaki, K., Yabusaki, K., Shirasawa, Y., ... Ikeda, Y. (1996). Thrombopoietin primes human platelet aggregation induced by shear stress and by multiple agonists. Blood, 87(11), 4664-4670.

Thrombopoietin primes human platelet aggregation induced by shear stress and by multiple agonists. / Oda, Atsushi; Miyakawa, Yoshitaka; Druker, Brian J.; Ozaki, Katsutoshi; Yabusaki, Katsumi; Shirasawa, Yoshiaki; Handa, Makoto; Kato, Takashi; Miyazaki, Hiroshi; Shimosaka, Akihiro; Ikeda, Yasuo.

In: Blood, Vol. 87, No. 11, 01.06.1996, p. 4664-4670.

Research output: Contribution to journalArticle

Oda, A, Miyakawa, Y, Druker, BJ, Ozaki, K, Yabusaki, K, Shirasawa, Y, Handa, M, Kato, T, Miyazaki, H, Shimosaka, A & Ikeda, Y 1996, 'Thrombopoietin primes human platelet aggregation induced by shear stress and by multiple agonists', Blood, vol. 87, no. 11, pp. 4664-4670.
Oda A, Miyakawa Y, Druker BJ, Ozaki K, Yabusaki K, Shirasawa Y et al. Thrombopoietin primes human platelet aggregation induced by shear stress and by multiple agonists. Blood. 1996 Jun 1;87(11):4664-4670.
Oda, Atsushi ; Miyakawa, Yoshitaka ; Druker, Brian J. ; Ozaki, Katsutoshi ; Yabusaki, Katsumi ; Shirasawa, Yoshiaki ; Handa, Makoto ; Kato, Takashi ; Miyazaki, Hiroshi ; Shimosaka, Akihiro ; Ikeda, Yasuo. / Thrombopoietin primes human platelet aggregation induced by shear stress and by multiple agonists. In: Blood. 1996 ; Vol. 87, No. 11. pp. 4664-4670.
@article{c399bf7e6e214b6a84fd1830b6117dfc,
title = "Thrombopoietin primes human platelet aggregation induced by shear stress and by multiple agonists",
abstract = "Recombinant thrombopoietin has been reported to stimulate megakaryocytopoiesis and thrombopoiesis and it may be quite useful to treat patients with low platelet counts after chemotherapy. As little is known regarding the possible activation of platelets by thrombopoietin, we examined the effects of thrombopoietin on platelet aggregation induced by shear stress and various agonists in native plasma. Using hirudin as an anticoagulant, thrombopoietin (1 to 100 ng/mL) enhanced platelet aggregation induced by 2 μmol/L adenosine-diphosphate (ADP) in a dose dependent fashion. The enhancement was not effected by treatment of platelets with 1 mmol/L aspirin plus SQ-29548 (a thromboxane antagonist, 1 μmol/L) but was inhibited by a soluble form of the thrombopoietin receptor, suggesting that the enhancement was mediated by the specific receptors and does not require thromboxane production. Epinephrine (1 μmol/L), which does not induce platelet aggregation in hirudin platelet rich plasma (PRP), did so in the presence of thrombopoietin (10 ng/mL). Thrombopoietin (10 ng/mL) also enhanced or primed platelet aggregation induced by collagen (0.5 μg/mL), thrombin, serotonin, and vasopressin. Thrombopoietin does not induce any rise in cytosolic ionized calcium concentration nor activation of protein kinase C, as estimated by phosphorylation of preckstrin, indicating that the priming effects of thrombopoietin does not require those processes. The ADP- or thrombin- induced rise in cytosolic ionized calcium concentration was not enhanced by thrombopoietin (100 ng/mL). Further, shear (ca. 90 dyn/cm2)-induced platelet aggregation was also potentiated by thrombopoietin. The priming effect on epinephrine-induced platelet aggregation in hirudin PRP was unique to thrombopoietin, with no effects seen using interleukin-6 (IL-6), IL-11, IL- 3, erythropoietin, granulocyte-colony stimulating factor, granulocyte macrophage-colony stimulating factor, or c-kit ligand. These data indicate that monitoring of platelet functions may be necessary in the clinical trials of thrombopoietin.",
author = "Atsushi Oda and Yoshitaka Miyakawa and Druker, {Brian J.} and Katsutoshi Ozaki and Katsumi Yabusaki and Yoshiaki Shirasawa and Makoto Handa and Takashi Kato and Hiroshi Miyazaki and Akihiro Shimosaka and Yasuo Ikeda",
year = "1996",
month = "6",
day = "1",
language = "English",
volume = "87",
pages = "4664--4670",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "11",

}

TY - JOUR

T1 - Thrombopoietin primes human platelet aggregation induced by shear stress and by multiple agonists

AU - Oda, Atsushi

AU - Miyakawa, Yoshitaka

AU - Druker, Brian J.

AU - Ozaki, Katsutoshi

AU - Yabusaki, Katsumi

AU - Shirasawa, Yoshiaki

AU - Handa, Makoto

AU - Kato, Takashi

AU - Miyazaki, Hiroshi

AU - Shimosaka, Akihiro

AU - Ikeda, Yasuo

PY - 1996/6/1

Y1 - 1996/6/1

N2 - Recombinant thrombopoietin has been reported to stimulate megakaryocytopoiesis and thrombopoiesis and it may be quite useful to treat patients with low platelet counts after chemotherapy. As little is known regarding the possible activation of platelets by thrombopoietin, we examined the effects of thrombopoietin on platelet aggregation induced by shear stress and various agonists in native plasma. Using hirudin as an anticoagulant, thrombopoietin (1 to 100 ng/mL) enhanced platelet aggregation induced by 2 μmol/L adenosine-diphosphate (ADP) in a dose dependent fashion. The enhancement was not effected by treatment of platelets with 1 mmol/L aspirin plus SQ-29548 (a thromboxane antagonist, 1 μmol/L) but was inhibited by a soluble form of the thrombopoietin receptor, suggesting that the enhancement was mediated by the specific receptors and does not require thromboxane production. Epinephrine (1 μmol/L), which does not induce platelet aggregation in hirudin platelet rich plasma (PRP), did so in the presence of thrombopoietin (10 ng/mL). Thrombopoietin (10 ng/mL) also enhanced or primed platelet aggregation induced by collagen (0.5 μg/mL), thrombin, serotonin, and vasopressin. Thrombopoietin does not induce any rise in cytosolic ionized calcium concentration nor activation of protein kinase C, as estimated by phosphorylation of preckstrin, indicating that the priming effects of thrombopoietin does not require those processes. The ADP- or thrombin- induced rise in cytosolic ionized calcium concentration was not enhanced by thrombopoietin (100 ng/mL). Further, shear (ca. 90 dyn/cm2)-induced platelet aggregation was also potentiated by thrombopoietin. The priming effect on epinephrine-induced platelet aggregation in hirudin PRP was unique to thrombopoietin, with no effects seen using interleukin-6 (IL-6), IL-11, IL- 3, erythropoietin, granulocyte-colony stimulating factor, granulocyte macrophage-colony stimulating factor, or c-kit ligand. These data indicate that monitoring of platelet functions may be necessary in the clinical trials of thrombopoietin.

AB - Recombinant thrombopoietin has been reported to stimulate megakaryocytopoiesis and thrombopoiesis and it may be quite useful to treat patients with low platelet counts after chemotherapy. As little is known regarding the possible activation of platelets by thrombopoietin, we examined the effects of thrombopoietin on platelet aggregation induced by shear stress and various agonists in native plasma. Using hirudin as an anticoagulant, thrombopoietin (1 to 100 ng/mL) enhanced platelet aggregation induced by 2 μmol/L adenosine-diphosphate (ADP) in a dose dependent fashion. The enhancement was not effected by treatment of platelets with 1 mmol/L aspirin plus SQ-29548 (a thromboxane antagonist, 1 μmol/L) but was inhibited by a soluble form of the thrombopoietin receptor, suggesting that the enhancement was mediated by the specific receptors and does not require thromboxane production. Epinephrine (1 μmol/L), which does not induce platelet aggregation in hirudin platelet rich plasma (PRP), did so in the presence of thrombopoietin (10 ng/mL). Thrombopoietin (10 ng/mL) also enhanced or primed platelet aggregation induced by collagen (0.5 μg/mL), thrombin, serotonin, and vasopressin. Thrombopoietin does not induce any rise in cytosolic ionized calcium concentration nor activation of protein kinase C, as estimated by phosphorylation of preckstrin, indicating that the priming effects of thrombopoietin does not require those processes. The ADP- or thrombin- induced rise in cytosolic ionized calcium concentration was not enhanced by thrombopoietin (100 ng/mL). Further, shear (ca. 90 dyn/cm2)-induced platelet aggregation was also potentiated by thrombopoietin. The priming effect on epinephrine-induced platelet aggregation in hirudin PRP was unique to thrombopoietin, with no effects seen using interleukin-6 (IL-6), IL-11, IL- 3, erythropoietin, granulocyte-colony stimulating factor, granulocyte macrophage-colony stimulating factor, or c-kit ligand. These data indicate that monitoring of platelet functions may be necessary in the clinical trials of thrombopoietin.

UR - http://www.scopus.com/inward/record.url?scp=9344225757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9344225757&partnerID=8YFLogxK

M3 - Article

VL - 87

SP - 4664

EP - 4670

JO - Blood

JF - Blood

SN - 0006-4971

IS - 11

ER -